Artwork

Konten disediakan oleh PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !

Thomas G. Martin, III, MD, Krina Patel, MD, MSc - Hitting the BCMA Target in Multiple Myeloma: Insights on CAR-T Therapy and Innovative Antibody Options

55:48
 
Bagikan
 

Manage episode 359210835 series 1118501
Konten disediakan oleh PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Go online to PeerView.com/FNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are updated on the latest evidence and management considerations on the use of BCMA antibodies and CAR-T cell therapy for the management of multiple myeloma (MM) in this new PeerView learning CME video recorded at the 2023 Tandem Meetings. Watch the MM experts clarify the most recent practice-changing evidence with BCMA-directed treatments and hear them provide insight on rapidly emerging future applications. Throughout, the experts deliver take-homes on the selection and sequential use of BCMA options, their use in earlier lines of therapy, and management of unique safety considerations. Get informed and see if you are hitting the target when it comes to your patients with MM! Upon completion of this activity, participants should be better able to: Summarize new and emerging evidence with novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T cell therapy, across several lines of treatment in MM; Apply evidence-based treatment plans with BCMA-targeting platforms for the sequential management of patients with MM; and Utilize proven tools to address practical aspects and safety considerations associated with the use of novel BCMA-targeted platforms, including dosing, scheduling, adherence, and AE management
  continue reading

66 episode

Artwork
iconBagikan
 
Manage episode 359210835 series 1118501
Konten disediakan oleh PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Go online to PeerView.com/FNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are updated on the latest evidence and management considerations on the use of BCMA antibodies and CAR-T cell therapy for the management of multiple myeloma (MM) in this new PeerView learning CME video recorded at the 2023 Tandem Meetings. Watch the MM experts clarify the most recent practice-changing evidence with BCMA-directed treatments and hear them provide insight on rapidly emerging future applications. Throughout, the experts deliver take-homes on the selection and sequential use of BCMA options, their use in earlier lines of therapy, and management of unique safety considerations. Get informed and see if you are hitting the target when it comes to your patients with MM! Upon completion of this activity, participants should be better able to: Summarize new and emerging evidence with novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T cell therapy, across several lines of treatment in MM; Apply evidence-based treatment plans with BCMA-targeting platforms for the sequential management of patients with MM; and Utilize proven tools to address practical aspects and safety considerations associated with the use of novel BCMA-targeted platforms, including dosing, scheduling, adherence, and AE management
  continue reading

66 episode

すべてのエピソード

×
 
Loading …

Selamat datang di Player FM!

Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.

 

Panduan Referensi Cepat